These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31227810)

  • 21. [Study of measles history, vaccination, antibody status, and vaccination effectiveress for school teachers].
    Ichinohe S; Ogawa T
    Kansenshogaku Zasshi; 2011 May; 85(3):263-7. PubMed ID: 21706846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Waning of vaccine-induced immunity: is it a problem in Africa?
    Aaby P; Cisse B; Simondon F; Samb B; Soumaré M; Whittle H
    Am J Epidemiol; 1999 Feb; 149(4):304-5. PubMed ID: 10025471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing incidence of subacute sclerosing panencephalitis in infants: a collateral effect of under-vaccination.
    Pittet LF; Posfay-Barbe KM
    Clin Microbiol Infect; 2020 Jun; 26(6):662-664. PubMed ID: 32088332
    [No Abstract]   [Full Text] [Related]  

  • 24. A population profile of measles susceptibility in Tianjin, China.
    Boulton ML; Wang X; Zhang Y; Montgomery JP; Wagner AL; Carlson BF; Ding Y; Li X; Gillespie B; Su X
    Vaccine; 2016 Jun; 34(27):3037-3043. PubMed ID: 27151881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of herd immunity in control of measles.
    Black FL
    Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of immunity against measles in persons immunized with Edmonston-Zagreb vaccine.
    abu Eldan J; Borćić B; Smerdel S
    Acta Med Croatica; 1991; 45(4-5):297-304. PubMed ID: 1726513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A re-emerging infection?
    Broy C; Williamson N; Morris J
    South Med J; 2009 Mar; 102(3):299-300. PubMed ID: 19204645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
    Trier H; Rønne T
    Ugeskr Laeger; 1992 Jul; 154(29):2008-13. PubMed ID: 1509566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroepidemiology of measles in Addis Ababa, Ethiopia: implications for control through vaccination.
    Enquselassie F; Ayele W; Dejene A; Messele T; Abebe A; Cutts FT; Nokes DJ
    Epidemiol Infect; 2003 Jun; 130(3):507-19. PubMed ID: 12825737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economic cost of measles: Healthcare, public health and societal costs of the 2012-13 outbreak in Merseyside, UK.
    Ghebrehewet S; Thorrington D; Farmer S; Kearney J; Blissett D; McLeod H; Keenan A
    Vaccine; 2016 Apr; 34(15):1823-31. PubMed ID: 26944712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks of non-vaccination.
    Launay O
    Med Mal Infect; 2020 Feb; 50(1):1-2. PubMed ID: 31640882
    [No Abstract]   [Full Text] [Related]  

  • 32. Live viral vaccines in the control of highly infectious diseases: measles and varicella.
    Frenkel LD
    Pediatr Ann; 2004 Sep; 33(9):584-9. PubMed ID: 15462573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Serologic assessment of measles herd immunity in the north-western region of Romania].
    Brumboiu I; Gocan G; Bocşan IS; Soşa I; Sava A; Ursu L; Olariu O; Paştină I; Simionca L
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(3):616-22. PubMed ID: 16607760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measles transmission during a large outbreak in California.
    Worden L; Ackley SF; Zipprich J; Harriman K; Enanoria WTA; Wannier R; Porco TC
    Epidemics; 2020 Mar; 30():100375. PubMed ID: 31735584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimum attack rate for measuring measles vaccine efficacy.
    Nourjah P; Frerichs RR
    Int J Epidemiol; 1995 Aug; 24(4):834-41. PubMed ID: 8550283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune responses to measles and measles vaccine: challenges for measles control.
    Moss WJ; Polack FP
    Viral Immunol; 2001; 14(4):297-309. PubMed ID: 11792060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months.
    Gans HA; Arvin AM; Galinus J; Logan L; DeHovitz R; Maldonado Y
    JAMA; 1998 Aug; 280(6):527-32. PubMed ID: 9707142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability in Humoral Immunity to Measles Vaccine: New Developments.
    Haralambieva IH; Kennedy RB; Ovsyannikova IG; Whitaker JA; Poland GA
    Trends Mol Med; 2015 Dec; 21(12):789-801. PubMed ID: 26602762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethics and vaccination.
    Krantz I; Sachs L; Nilstun T
    Scand J Public Health; 2004; 32(3):172-8. PubMed ID: 15204177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits.
    Mina MJ
    J Infect; 2017 Jun; 74 Suppl 1():S10-S17. PubMed ID: 28646947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.